+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neuropsychotherapeutics. Advances in Pharmacology Volume 86

  • Book

  • August 2019
  • Elsevier Science and Technology
  • ID: 4768598

Neuropsychotherapeutics, Volume 86, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field, with this updated edition including sections on Pharmacotherapy of psychiatric disorders, Allosteric mechanisms for neuropsychopharmacology, Lipid rafts, Rapid-acting antidepressants, mGlu2/3 receptor antagonists, Nitric oxide: antidepressant mechanisms and inflammation, Anxiety disorders, mGlu receptors and schizophrenia, mAChR ligands for schizophrenia and addiction, PDE10 inhibitors, Obsessive-compulsive disorder, Addiction disorders (including eating), Dopamine D1 PAMs as a New Mode for Treatment of Neuropsychiatric Disorders, and more.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. GPCR drug discovery-moving beyond the orthosteric to the allosteric domainChristian C. Felder2. Lipid rafts in psychiatryNathan H. Wray and Mark M. Rasenick3. Rapid-acting antidepressantsJeffrey M. Witkin, Anna E. Martin, Lalit K. Golani, Nina Z. Xu and Jodi L. Smith4. mGlu2/3 receptor antagonistsShigeyuki Chaki5. Nitric oxide: Antidepressant mechanisms and inflammationMehdi Ghasemi6. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disordersLaura B. Teal, Robert W. Gould, Andrew S. Felts and Carrie K. Jones7. Medications development for food-based and drug use disordersFernando B. de Moura, Stephen J. Kohut and Jack Bergman8. Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic researchErik Z. Woody, Kurt Leroy Hoffman and Henry Szechtman9. Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disordersKjell A. Svensson, Junliang Hao and Robert F. Bruns